Last reviewed · How we verify
MenACWY
MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y.
MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | MenACWY |
|---|---|
| Also known as | Menveo |
| Sponsor | LimmaTech Biologics AG |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains polysaccharide capsules from Neisseria meningitidis serogroups A, C, W, and Y conjugated to a protein carrier (CRM197), which enhances immunogenicity and T-cell dependent immune responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these four serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in infants, children, adolescents, and adults
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Fever
- Myalgia
- Headache
Key clinical trials
- Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. (PHASE2)
- Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women (NA)
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
- Increasing Vaccine Uptake Among Adolescents in the Rural South (NA)
- Investigating a Vaccine Against COVID-19 (PHASE2, PHASE3)
- A Study of a Candidate COVID-19 Vaccine (COV001) (PHASE1, PHASE2)
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MenACWY CI brief — competitive landscape report
- MenACWY updates RSS · CI watch RSS
- LimmaTech Biologics AG portfolio CI